Novartis’ MS therapy Kesimpta wins NICE backing

21st April 2021 Uncategorised 0

First self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS

More: Novartis’ MS therapy Kesimpta wins NICE backing
Source: News